Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Terumo Corporation is a Japan-based global medical device manufacturer with three core divisions: Cardiac & Vascular (interventional cardiology devices, drug-eluting stents, catheters), General Hospital (blood management systems, infusion pumps, diabetes care), and Blood & Cell Technologies (blood collection systems, therapeutic apheresis). The company operates manufacturing facilities across Japan, US, Europe, and Asia, with approximately 40% of revenue from Japan and 60% from international markets, competing against Medtronic, Abbott, and Boston Scientific in high-margin interventional devices.
Terumo generates revenue through a mix of high-margin consumable medical devices (catheters, stents, blood bags) that require repeat purchases and durable capital equipment (infusion pumps, apheresis systems) with recurring service contracts. The cardiac intervention portfolio commands premium pricing due to clinical outcomes data and physician preference, while hospital products benefit from long-term supply agreements with hospital networks. Gross margins of 54% reflect manufacturing scale in Japan and cost-effective Asian production, with pricing power derived from regulatory approvals (FDA, CE Mark, PMDA) and established distribution relationships with hospitals and group purchasing organizations.
Cardiac & Vascular segment growth rates, particularly drug-eluting stent market share in US and Europe against Abbott's Xience and Boston Scientific's Synergy platforms
Japanese yen exchange rate fluctuations (60% of revenue is international, primarily USD and EUR denominated, creating translation exposure)
Hospital capital equipment spending trends in developed markets, driven by elective procedure volumes and healthcare system budgets
Regulatory approvals and clinical trial results for pipeline products, especially next-generation cardiovascular devices and neurovascular technologies
China market penetration and volume-based procurement (VBP) pricing impact on interventional cardiology products
Healthcare cost containment pressures globally, including Japan's biennial reimbursement cuts, US hospital consolidation driving pricing pressure, and China's volume-based procurement (VBP) program mandating 50-70% price reductions for interventional devices
Technological disruption from minimally invasive alternatives, including transcatheter heart valve procedures reducing need for traditional cardiac surgery devices, and digital health monitoring potentially displacing some hospital equipment
Regulatory pathway complexity and lengthening approval timelines for new devices, particularly in US (FDA PMA process) and Europe (MDR requirements), increasing R&D costs and time-to-market
Intense competition in drug-eluting stents from Abbott (40%+ global market share with Xience platform) and Boston Scientific, with limited differentiation beyond clinical trial data and physician relationships
Market share erosion in blood management systems from Haemonetics and Fresenius Kabi, particularly in North American hospital networks consolidating suppliers
Chinese domestic manufacturers (MicroPort, Lepu Medical) gaining share in Asia-Pacific with lower-cost cardiovascular devices, supported by government procurement preferences
Currency translation risk with 60% of revenue in foreign currencies (primarily USD, EUR, CNY) while cost base is largely yen-denominated, creating earnings volatility from exchange rate fluctuations without full hedging
Pension obligations typical of large Japanese manufacturers, though current funded status appears adequate based on ROA/ROE metrics
Moderate capex intensity (8% of revenue based on $82.4B capex) for manufacturing capacity expansion and automation, requiring sustained free cash flow generation
moderate - Medical device demand is partially insulated from economic cycles as cardiovascular procedures are often medically necessary rather than discretionary. However, hospital capital equipment purchases (infusion pumps, apheresis systems) are deferred during economic downturns when hospital budgets tighten. Elective cardiac procedures show modest correlation with consumer confidence and employment levels, as patients with insurance coverage may delay non-urgent interventions during recessions. Emerging market growth is more GDP-sensitive as healthcare infrastructure investment tracks economic expansion.
Rising interest rates create moderate headwinds through multiple channels: (1) hospital capital equipment financing becomes more expensive, potentially delaying large system purchases; (2) higher discount rates compress valuation multiples for medical device stocks trading at premium P/E ratios; (3) stronger USD (typically correlated with rising US rates) creates translation headwinds for Terumo's international revenue when converted to yen. However, the company's low debt/equity ratio (0.26) minimizes direct financing cost impact. Japanese monetary policy divergence from US rates also affects yen competitiveness for exports.
Minimal direct credit exposure as Terumo sells primarily to hospitals, healthcare systems, and distributors with stable payment histories. Accounts receivable risk is low given customer base of established institutions. However, hospital financial stress during credit tightening can lead to extended payment terms and pressure on device pricing during contract renewals. Indirect exposure exists through hospital access to capital markets for equipment financing.
value - The stock's 30.8% decline over the past year, combined with reasonable valuation metrics (2.7x P/S, 11.5x EV/EBITDA) and strong cash generation (695.5% FCF yield appears anomalous, likely data error, but $128.4B FCF on $18.5B market cap suggests 6.9x FCF multiple), attracts value investors seeking quality healthcare exposure at depressed multiples. The 54% gross margin and consistent profitability (11.3% net margin) appeal to investors prioritizing business quality over growth. Dividend-focused investors may also be attracted if the company maintains typical Japanese corporate payout policies.
moderate - Medical device stocks typically exhibit lower volatility than broader markets due to recurring revenue from consumables and essential healthcare demand. However, Terumo faces elevated volatility from: (1) currency translation swings given international revenue mix, (2) binary events around regulatory approvals and clinical trial results, (3) quarterly earnings sensitivity to hospital capital spending cycles. The recent 33.9% six-month decline suggests above-average volatility, potentially driven by Japan-specific concerns or competitive pressures in core markets.
